4D Molecular Therapeutics used a presentation at Morgan Stanley's 24th Annual Global Healthcare Conference, according to a transcript dated September 14, 2026, to detail progress on its lead gene therapy, 4D-150, and its commercial plans for retinal indications. The company said the program uses the R100 vector and is being developed for large ophthalmology markets, including diabetic macular edema. Founder and Chief Executive Officer David Kirn said the company is applying directed evolution to create optimized vectors that lower doses, reduce cost of goods and improve safety and efficacy relative to traditional gene therapy.
Financially, 4D Molecular Therapeutics reported cash and cash equivalents of $431 million as of June 30, 2024, and said its cash runway extends into the second half of 2028. The company's stock had returned 102% over the past year, with a beta of 2.73, a market capitalization of $762 million, a current ratio of 8.03 and analyst price targets ranging from $18 to $37. The company also said it had received upfront payments north of $110 million from Otsuka Pharmaceutical for commercial rights across retinal indications in Asia-Pacific, a region it estimated at 10% to 15% of total global commercial value. 4D Molecular Therapeutics retained about 85% of global commercial rights.
Clinically, 4FRONT-1 and 4FRONT-2 each enrolled about 525 to 530 patients, ahead of schedule and slightly over-enrolled, increasing statistical power to more than 90% in the U.S. and globally. Top-line data from 4FRONT-1 are expected in the second quarter of 2025, with 4FRONT-2 data expected in the second half of 2025. The company said it expected to initiate a Phase III diabetic macular edema study in the fourth quarter of 2024 and provide a fourth-quarter 2024 update on 4D-710, its cystic fibrosis program, including FDA discussions and timing and operational details for 2027 data. A commercial-focused investor day was scheduled for October 21, 2024.
Trial design details included a non-inferiority margin of 3.9 letters for the global analysis, including Japan for Otsuka, and 4.5 letters for the U.S. analysis. 4FRONT-1 enrolled treatment-naive patients only, while 4FRONT-2 included more than 60% treatment-naive patients, along with recently diagnosed patients to meet European requests. The run-in period required either a 15% reduction in best-corrected visual acuity loss or complete fluid clearance on aflibercept before randomization, with central subfield thickness capped at 500 microns. Supplemental injections were allowed only at prespecified worsening thresholds: 10 letters of BCVA loss alone, 100 microns of CST worsening alone, or a combination of 5 letters and 50 microns. A 20-week Durezol taper was included in the regimen.
Earlier PRISM Phase I/II data covered more than 70 patients at the Phase III dose, comparing 1E10 and 3E10 mg per eye, and showed treatment-burden reductions in the 70% to 90% range that were durable through two years. The company said patient development began four and a half years earlier, when Libervant blinding episodes in diabetic macular edema had prompted caution, and that it has since moved to enrollment in frontline patients globally. The discussion referenced existing products including Eylea, Eylea HD, Beovu, Vabysmo, Durezol, aflibercept and Libervant.
Commercially, executives said the U.S. market includes more than 600,000 patients receiving regular anti-VEGF therapy across more than 800,000 eyes, with bilateral disease affecting more than 40% of patients and about 40% falling off anti-VEGF therapy by 18 months. An American Society of Retina Specialists survey cited in 2025 found that 60% of respondents called gene therapy the most exciting therapeutic modality in development. 4D Molecular Therapeutics planned a commercial team of 100 to 120 people, including 60 to 80 field employees focused on sales and reimbursement support. A commercial officer said the company's goal is to extend treatment durability by months, years or potentially a patient's lifetime, that 4D-150 fits into existing treatment workflows and that its economics could be better than current options, although calculated differently. The company said the commercial case starts with high unmet need and that its data have been compelling, while efficacy is comparable to other programs and safety data have stood apart.
